Astra And Byk Gulden End PPI Dispute
Astra of Sweden has reached agreement with competitor company Byk Gulden of Germany to end their patent dispute relating to the two firms' proton pump inhibitors, omeprazole and pantoprazole.
A short statement was issued jointly by the companies saying that they had agreed to terminate, with immediate effect, their ongoing dispute. All legal actions between the two firms and licensees are to be withdrawn, it said, adding that settlement will not involve any financial or other compensation. Legal proceedings had been started in 10 countries.
Herman Kullmer, a member of the management board of Byk Gulden's parent company Altana AG, told the Marketletter that he was unable to comment on the press release, as part of the settlement agreement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze